← Back to Clinical Trials
Recruiting NCT05264675

NCT05264675 Functional Outcome After EPL-rupture After Distal Radius Fracture

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05264675
Status Recruiting
Phase
Sponsor Vastra Gotaland Region
Condition Distal Radius Fracture
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2022-01-01
Primary Completion 2026-04-01

Trial Parameters

Condition Distal Radius Fracture
Sponsor Vastra Gotaland Region
Study Type OBSERVATIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 16 Years
Max Age N/A
Start Date 2022-01-01
Completion 2026-04-01
Interventions
primary sutureEIP-transfer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Rupture of the extensor pollicis longus, (EPL) is a common complication after distal radius fractures. A rupture prevents the thumb extension, which in turn has a negative impact on hand function. An EPL-rupture can either be surgically treated by primary suture, which means that the ends of the tendon are sutured. This is however not recommended if the tendon is weakened. In such cases the rupture can be treated by a transfer of, most often, extensor indicis proprius (EIP) to the thumb. Distal radius fractures are common and a rupture of the EPL-tendon is a known complication thar interferes with hand function and therefore more studies on this patient group are warranted. The aim of this prospective study is to compare regaining of thumb function after surgery, with the non-injured side, after primary suture and EIP-transfer after EPL-rupture as a complication following distal radius fracture.

Eligibility Criteria

Inclusion criteria: * Distal Radius Fracture * EPL-rupture Exclusion Criteria: * comorbidity interfering with thumb function * inability to fill in forms

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology